🔎 Trials Near Me

Beranda › Penyakit Paru Interstisial › Kansas › Kansas City

Uji klinis Penyakit Paru Interstisial di Kansas City, KS

13 studi untuk Penyakit Paru Interstisial mencari peserta di lokasi sekitar Kansas City (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression

Menerima pesertaFase 3
  • University of Kansas Medical Center, Kansas City
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT07540988

A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis

Menerima pesertaFase 3
  • University of Kansas Medical Center, Kansas City
Usia 40 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07201922

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Menerima pesertaFase 3
  • USA002, Kansas City
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT07179380

A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

Menerima pesertaFase 2
  • University of Kansas Medical Center, Kansas City
Usia 40 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT06968845

A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD

Menerima pesertaFase 2
  • Clinical Research Site, Kansas City
Usia 18 hingga 85 · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT07333183

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Menerima pesertaStudi observasional
  • University of Kansas Medical Center, Kansas City
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 26 Agu 2026 · NCT06388421

Platform Clinical Study for Conquering Scleroderma

Menerima pesertaFase 2
  • University of Kansas School of Medicine, Kansas City
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Agu 2026 · NCT06195072

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

Menerima pesertaFase 2/3
  • University of Kansas Medical Center, Kansas City
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT06328777

A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)

Menerima pesertaFase 2
  • The University of Kansas Medical Center Research Institute, Kansas City
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 10 Agu 2026 · NCT07175038

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

Menerima pesertaFase 3
  • University of Kansas Medical Center, Kansas City
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Jul 2026 · NCT05943535

Interstitial Lung Disease Research Unit Biobank

Menerima pesertaStudi observasional
  • The University of Kansas Medical Center, Kansas City
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Jul 2026 · NCT05392881

Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease

Menerima pesertaFase 1Sukarelawan sehat diterima
  • University of Kansas Medical Center, Kansas City
Usia 3 ke atas · Semua jenis kelamin · Diperbarui 6 Mei 2026 · NCT04624490

Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease

Menerima pesertaStudi observasional
  • University of Kansas, Kansas City
Usia 18 hingga 90 · Semua jenis kelamin · Diperbarui 3 Mei 2024 · NCT06397677

Uji klinis Penyakit Paru Interstisial di kota lain

Studi lain di Kansas City

Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.